GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Cyclically Adjusted Price-to-FCF

Renovaro (FRA:2Q5) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Renovaro Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Renovaro Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Renovaro's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Cyclically Adjusted Price-to-FCF Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Renovaro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Renovaro's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Renovaro's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovaro's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Renovaro's Cyclically Adjusted Price-to-FCF falls into.



Renovaro Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Renovaro's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Renovaro's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.023/131.7762*131.7762
=-0.023

Current CPI (Mar. 2024) = 131.7762.

Renovaro Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.030 100.560 -0.039
201409 -0.038 100.428 -0.050
201412 -0.079 99.070 -0.105
201503 -0.198 99.621 -0.262
201506 -0.167 100.684 -0.219
201509 -0.039 100.392 -0.051
201512 -0.064 99.792 -0.085
201603 -0.007 100.470 -0.009
201606 -0.029 101.688 -0.038
201609 -0.030 101.861 -0.039
201612 -0.032 101.863 -0.041
201703 -0.003 102.862 -0.004
201706 -0.036 103.349 -0.046
201709 -0.034 104.136 -0.043
201712 -0.030 104.011 -0.038
201803 -0.057 105.290 -0.071
201806 -0.038 106.317 -0.047
201809 -0.050 106.507 -0.062
201812 -0.051 105.998 -0.063
201903 -0.068 107.251 -0.084
201906 -0.050 108.070 -0.061
201909 -0.037 108.329 -0.045
201912 -0.051 108.420 -0.062
202003 -0.076 108.902 -0.092
202006 -0.043 108.767 -0.052
202009 -0.050 109.815 -0.060
202012 -0.044 109.897 -0.053
202103 -0.042 111.754 -0.050
202106 -0.223 114.631 -0.256
202109 -0.086 115.734 -0.098
202112 -0.078 117.630 -0.087
202203 -0.048 121.301 -0.052
202206 -0.054 125.017 -0.057
202209 -0.049 125.227 -0.052
202212 -0.060 125.222 -0.063
202303 -0.055 127.348 -0.057
202306 -0.036 128.729 -0.037
202309 -0.040 129.860 -0.041
202312 -0.044 129.419 -0.045
202403 -0.023 131.776 -0.023

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Renovaro  (FRA:2Q5) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Renovaro Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Renovaro's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (FRA:2Q5) Business Description

Industry
Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines